Alnylam Pharmaceuticals Inc (ALNY)
Sector • Healthcare Industry • Major Pharmaceutical Preparations |
Industry • Major Pharmaceutical Preparations |
Sector • Healthcare |
Exceptional 29.59%, improvement in Revenues by the company during the financial time-frame ending December 31 2022
ALNY announced fourth quarter of 2022 operating deficit of $-188.614 million
Published Mar 26 2023
CSIMarket Team / CSIMarket.com
For the fourth quarter of 2022 company decreased a loss per share of $-1.64 per share compare to $-2.16 a year prior and earnings per share improved from $-3.32 per share from the prior financial reporting period.
Revenues increased rapidly by 29.59 % to $335.04 millions from $258.54 millions in the similar financial reporting period a year prior and sequentially Revenues improved by 26.76 % from $264.31 millions.
In the fourth quarter of 2022 Alnylam Pharmaceuticals Inc reported net loss of $-207.493 million, instead of deficit of $-258.460 millions in the similar financial reporting period a year ago.
ALNY announced loss of $-1,131.16 millions and Revenues of $1.04 billions in the financial year 2022.
Net loss per share has widen to $-9.30 from $-7.20 in prior financial year, while Revenues improved by 22.88 % from $844.29 millions a year prior.
Alnylam Pharmaceuticals Inc is expected to report next financial results on April 27, 2023.
Revenues increased rapidly by 29.59 % to $335.04 millions from $258.54 millions in the similar financial reporting period a year prior and sequentially Revenues improved by 26.76 % from $264.31 millions.
In the fourth quarter of 2022 Alnylam Pharmaceuticals Inc reported net loss of $-207.493 million, instead of deficit of $-258.460 millions in the similar financial reporting period a year ago.
ALNY announced loss of $-1,131.16 millions and Revenues of $1.04 billions in the financial year 2022.
Net loss per share has widen to $-9.30 from $-7.20 in prior financial year, while Revenues improved by 22.88 % from $844.29 millions a year prior.
Alnylam Pharmaceuticals Inc is expected to report next financial results on April 27, 2023.